Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, WS Amati Global Innovation Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"U. Group while defending software, defense, and vision positions amidst short-term volatility."
During Q4 2025, the global markets saw positive momentum with the MSCI ACWI up 3.4% amid easing monetary policy and softer US/China trade tensions. AI continued to dominate debate, driving strong performance in memory semiconductors (Samsung, SK Hynix) and photonics (Lumentum). Eli Lilly also contributed strongly with clinical and commercial success in GLP1 treatments. The fund used short-term market weakness to add to positions in Cognex, Chemring, and PTC. New positions were established in Fabrinet (photonics) and H.U. Group (diagnostics), funded by exiting Yageo where the investment case has played out. The manager remains highly constructive on market valuations, emphasizing a concentrated portfolio approach capped at 40 stocks.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: WS Amati Global Innovation Fund capitalized on AI infrastructure and biotech gains in Q4 2025, actively purchasing underpriced growth names like Fabrinet and H.U. Group while defen...
Growth Outlook
Market outlook remains high conviction: WS Amati Global Innovation Fund capitalized on AI infrastructure and biotech gains in Q4 2025, actively purchasing underpriced growth names like Fabrinet and H.U. Group while defen...
Risk Appetite
Risk appetite posture is above average conviction: WS Amati Global Innovation Fund capitalized on AI infrastructure and biotech gains in Q4 2025, actively purchasing underpriced growth names like Fabrinet and H.U. Group while defen...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. WS Amati Global Innovation Fund capitalized on AI infrastructure and biotech gains in Q4 2025, actively purchasing underpriced growth names like Fabrinet and H.U. Group while defen...
Forward Guidance
Forward guidance signal: WS Amati Global Innovation Fund capitalized on AI infrastructure and biotech gains in Q4 2025, actively purchasing underpriced growth names like Fabrinet and H.U. Group while defen...
Language Signal
Tone analysis indicates above average conviction language: WS Amati Global Innovation Fund capitalized on AI infrastructure and biotech gains in Q4 2025, actively purchasing underpriced growth names like Fabrinet and H.U. Group while defen...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. WS Amati Global Innovation Fund capitalized on AI infrastructure and biotech gains in Q4 2025, actively purchasing underpriced growth names like Fabrinet and H.U. Group while defen...
Opportunity Density
Opportunity density index indicates high conviction actionable entry points. WS Amati Global Innovation Fund capitalized on AI infrastructure and biotech gains in Q4 2025, actively purchasing underpriced growth names like Fabrinet and H.U. Group while defen...
Time Horizon
Investment time horizon reflects a high conviction orientation. WS Amati Global Innovation Fund capitalized on AI infrastructure and biotech gains in Q4 2025, actively purchasing underpriced growth names like Fabrinet and H.U. Group while defen...
